Unicycive Therapeutics (UNCY) Total Current Liabilities (2020 - 2026)

Unicycive Therapeutics (UNCY) has 7 years of Total Current Liabilities data on file, last reported at $26.5 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 58.82% year-over-year to $26.5 million; the trailing twelve-month figure through Mar 2026 stood at $26.5 million (up 58.82% YoY), and the FY2025 full-year result was $18.9 million, down 21.48% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $26.5 million, up from $18.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $30.3 million in Q1 2024 and bottomed at $2.4 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $15.4 million (2023), against an average of $14.4 million.
• The widest annual swing landed in 2022, when Total Current Liabilities soared 603.44%; it then plunged 44.93% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $3.3 million in 2022, then surged by 433.92% to $17.5 million in 2023, then surged by 37.56% to $24.1 million in 2024, then fell by 21.48% to $18.9 million in 2025, then soared by 39.85% to $26.5 million in 2026.
• The last three Total Current Liabilities figures came in at $26.5 million (Q1 2026), $18.9 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.

Peer Comparison